Skip to content
1601-RIG-I Targeting for PANoptosis Cancer Immunotherapy episode artwork

Sep 23, 2026 16 min

1601-RIG-I Targeting for PANoptosis Cancer Immunotherapy

from Paper Talk

The research introduces Hemin-His-Mn, a tumor-targeting nanozyme designed to overcome cancer immunotherapy resistance by triggering PANoptosis, a robust form of programmed cell death. This innovative nanomedicine acts by binding to the RIG-I protein, alleviating its autoinhibition to initiate PANoptosome assembly while simultaneously generating lethal reactive oxygen species to accelerate cell destruction. By inducing this immunogenic death, the platform effectively releases danger signals that reprogram the tumor microenvironment and activate a potent T cell-mediated immune response. Preclinical studies demonstrate that this dual-action strategy successfully shrinks tumors in mouse models and synergizes with immune checkpoint inhibitors to reverse treatment resistance. Ultimately, the study identifies RIG-I as a master sensor for PANoptosis and provides a clinically translatable modality for precision cancer immunotherapy. References: Dong S, Yuan Y, Cao H, et al. A RIG-I targeting nanozyme induces PANoptosis for cancer immunotherapy[J]. Nature Communications, 2026, 17: 6311. 前往小宇宙评论区与主播互动

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

1601-RIG-I Targeting for PANoptosis Cancer Immunotherapy

0:00 16:24

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Paper Talk?

This episode is 16 minutes long.

When was this Paper Talk episode published?

This episode was published on September 23, 2026.

Can I download this Paper Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.